FR09C0010I1 - - Google Patents

Info

Publication number
FR09C0010I1
FR09C0010I1 FR09C0010C FR09C0010I1 FR 09C0010 I1 FR09C0010 I1 FR 09C0010I1 FR 09C0010 C FR09C0010 C FR 09C0010C FR 09C0010 I1 FR09C0010 I1 FR 09C0010I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR09C0010I1 publication Critical patent/FR09C0010I1/fr
Application granted granted Critical
Publication of FR09C0010I2 publication Critical patent/FR09C0010I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
FR09C0010C 2002-01-24 2009-03-12 Active FR09C0010I2 (enrdf_load_html_response)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35138402P 2002-01-24 2002-01-24
PCT/CA2003/000084 WO2003062200A2 (en) 2002-01-24 2003-01-22 Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists

Publications (2)

Publication Number Publication Date
FR09C0010I1 true FR09C0010I1 (enrdf_load_html_response) 2009-04-17
FR09C0010I2 FR09C0010I2 (enrdf_load_html_response) 2009-12-18

Family

ID=27613492

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0010C Active FR09C0010I2 (enrdf_load_html_response) 2002-01-24 2009-03-12

Country Status (39)

Country Link
US (6) US20030158246A1 (enrdf_load_html_response)
EP (3) EP2295409B1 (enrdf_load_html_response)
JP (2) JP4008885B2 (enrdf_load_html_response)
KR (2) KR100859230B1 (enrdf_load_html_response)
CN (3) CN101092388A (enrdf_load_html_response)
AR (1) AR038136A1 (enrdf_load_html_response)
AT (1) ATE414690T1 (enrdf_load_html_response)
AU (1) AU2003202343B2 (enrdf_load_html_response)
BR (1) BR0307050A (enrdf_load_html_response)
CA (1) CA2471952C (enrdf_load_html_response)
CY (3) CY1108841T1 (enrdf_load_html_response)
DE (2) DE60324767D1 (enrdf_load_html_response)
DK (2) DK1470107T3 (enrdf_load_html_response)
DO (1) DOP2003000566A (enrdf_load_html_response)
EA (1) EA006134B1 (enrdf_load_html_response)
EC (1) ECSP045203A (enrdf_load_html_response)
EG (1) EG24978A (enrdf_load_html_response)
ES (2) ES2391747T3 (enrdf_load_html_response)
FR (1) FR09C0010I2 (enrdf_load_html_response)
GE (1) GEP20074078B (enrdf_load_html_response)
HR (1) HRP20040665B1 (enrdf_load_html_response)
IL (3) IL162825A0 (enrdf_load_html_response)
IS (2) IS2633B (enrdf_load_html_response)
JO (1) JO2481B1 (enrdf_load_html_response)
LU (1) LU91534I2 (enrdf_load_html_response)
MX (1) MXPA04007167A (enrdf_load_html_response)
MY (1) MY137040A (enrdf_load_html_response)
NL (1) NL300377I2 (enrdf_load_html_response)
NO (3) NO327322B1 (enrdf_load_html_response)
NZ (1) NZ533786A (enrdf_load_html_response)
PE (1) PE20030982A1 (enrdf_load_html_response)
PL (1) PL208527B1 (enrdf_load_html_response)
PT (2) PT2045241E (enrdf_load_html_response)
RS (2) RS20100338A (enrdf_load_html_response)
SI (2) SI2045241T1 (enrdf_load_html_response)
TW (1) TWI259080B (enrdf_load_html_response)
UA (1) UA75520C2 (enrdf_load_html_response)
WO (1) WO2003062200A2 (enrdf_load_html_response)
ZA (1) ZA200404999B (enrdf_load_html_response)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217725B2 (en) * 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
US7273883B2 (en) * 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
WO2004104205A2 (en) * 2003-05-16 2004-12-02 Merck & Co., Inc. Enzymatic preparation of chiral indole esters
CN1791577A (zh) * 2003-05-20 2006-06-21 麦克弗罗斯特加拿大有限公司 氟－甲基磺酰取代的环烷并吲哚和它们作为前列腺素d2拮抗剂的用途
ATE464048T1 (de) * 2003-08-07 2010-04-15 Merck Sharp & Dohme Behandlung von alzheimer-krankheit und verwandten zuständen
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
RU2387652C2 (ru) 2004-03-11 2010-04-27 Актелион Фармасьютиклз Лтд Производные тетрагидропиридоиндола
TWI344954B (en) * 2004-04-02 2011-07-11 Merck Sharp & Dohme Asymmetric hydrogenation process
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
US20070299122A1 (en) * 2004-11-08 2007-12-27 Tobert Jonathan A Method of Treating Pathological Blushing
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006068162A1 (ja) * 2004-12-24 2006-06-29 Shionogi & Co., Ltd. 慢性閉塞性肺疾患の治療剤
CA2594280C (en) * 2004-12-27 2013-04-23 Anja Fecher 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
CA2598273A1 (en) * 2005-02-17 2006-08-24 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
CN101160125A (zh) * 2005-04-13 2008-04-09 默克公司 烟酸受体激动剂、含有这样化合物的组合物和治疗方法
ES2372701T3 (es) 2005-07-22 2012-01-25 Shionogi & Co., Ltd. Derivado de indol que tiene actividad antagonista del receptor de pgd2.
EP1911759A4 (en) 2005-07-22 2010-07-21 Shionogi & Co AZAINDOL DERIVATIVE ANTAGONISTIC EFFECT ON PGD2 RECEPTOR
US8143285B2 (en) 2005-09-06 2012-03-27 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
ES2618352T3 (es) 2006-06-16 2017-06-21 The Trustees Of The University Of Pennsylvania Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética
MY147588A (en) 2006-08-07 2012-12-31 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
EP2300425A4 (en) 2008-06-24 2012-03-21 Panmira Pharmaceuticals Llc PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS
WO2010030360A1 (en) 2008-09-11 2010-03-18 Arena Pharmaceuticals, Inc. 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
EP2346866B1 (en) * 2008-09-25 2013-11-27 Merck Canada Inc. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US9180114B2 (en) * 2008-11-26 2015-11-10 President And Fellows Of Harvard College Neurodegenerative diseases and methods of modeling
US8882678B2 (en) * 2009-03-13 2014-11-11 Atrium Medical Corporation Pleural drainage system and method of use
KR101444572B1 (ko) 2010-03-22 2014-09-24 액테리온 파마슈티칼 리미티드 3-(헤테로아릴-아미노)-1,2,3,4-테트라히드로-9ｈ-카르바졸 유도체 및 이의 프로스타글란딘 ｄ2 수용체 조절제로서의 용도
ES2596581T3 (es) 2011-04-14 2017-01-10 Actelion Pharmaceuticals Ltd. Derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indol acético y su uso como moduladores del receptor de prostaglandina D2
JP5841361B2 (ja) * 2011-06-29 2016-01-13 壽製薬株式会社 三環性化合物及びそれを含有する医薬組成物
AR088377A1 (es) * 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102659664B (zh) * 2012-03-28 2015-01-21 中国计量学院 合成分离拉洛皮兰及其类似物的方法
FR3000395A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee
FR3000399B1 (fr) * 2012-12-31 2015-03-27 Galderma Res & Dev Utilisation topique du laropiprant pour le traitement de la rosacee
PT3119779T (pt) 2014-03-17 2018-10-19 Idorsia Pharmaceuticals Ltd Derivados de ácido azaindol acético e sua utilização como modeladores de recetor d2 de prostaglandina
US9850241B2 (en) 2014-03-18 2017-12-26 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
JP6770522B2 (ja) 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
CA2993893A1 (en) 2015-09-15 2017-03-23 Idorsia Pharmaceuticals Ltd Crystalline forms
WO2019181592A1 (ja) 2018-03-19 2019-09-26 三井化学株式会社 表示素子用封止材およびその硬化物、有機ｅｌ素子用枠封止材、ならびに有機ｅｌ素子用面封止材

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) * 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) * 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
IL81325A (en) * 1986-01-23 1990-11-29 Merck Frosst Canada Inc Tetrahydrocarbazole 1-alkanoic acids and pharmaceutical compositions containing them
US5021447A (en) * 1986-01-23 1991-06-04 Merck Frosst Canada, Inc. Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
US5221678A (en) 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
GB9101375D0 (en) 1991-01-22 1991-03-06 Erba Carlo Spa N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
EP0769958B1 (en) 1994-07-11 2003-04-16 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996031206A2 (en) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
WO1996040781A1 (en) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
DE69636478T2 (de) 1995-06-21 2007-04-19 Shionogi & Co., Ltd. Bizyklische aminoderivate und enthaltende pgd2-antagonisten
AU6311996A (en) 1995-07-06 1997-02-05 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
JP3215441B2 (ja) 1996-12-13 2001-10-09 塩野義製薬株式会社 ベンゾチオフェンカルボン酸アミド誘導体およびそれを含有するｐｇｄ２拮抗剤
ES2241283T3 (es) 1998-06-03 2005-10-16 SHIONOGI & CO., LTD. Remedios para el tratamiento del prurito que contienen antagonistas de pgd2.
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives

Also Published As

Publication number Publication date
RS51672B (en) 2011-10-31
EP2295409A1 (en) 2011-03-16
ECSP045203A (es) 2004-09-28
NZ533786A (en) 2006-11-30
AU2003202343C1 (en) 2003-09-02
US20060069148A1 (en) 2006-03-30
DK2045241T3 (da) 2012-10-15
EP2295409B1 (en) 2014-07-02
DE122009000022I1 (de) 2009-08-06
EP2045241B1 (en) 2012-07-04
MXPA04007167A (es) 2004-10-29
CN101851191A (zh) 2010-10-06
EA006134B1 (ru) 2005-10-27
ATE414690T1 (de) 2008-12-15
US20080033028A1 (en) 2008-02-07
KR20070056166A (ko) 2007-05-31
IS7329A (is) 2004-06-21
JP2005518413A (ja) 2005-06-23
EP2045241A1 (en) 2009-04-08
IL162825A (en) 2010-12-30
DOP2003000566A (es) 2003-09-15
MY137040A (en) 2008-12-31
EP1470107B1 (en) 2008-11-19
CA2471952A1 (en) 2003-07-31
EA200400971A1 (ru) 2004-12-30
BR0307050A (pt) 2004-10-26
IS2633B (is) 2010-06-15
JO2481B1 (en) 2009-01-20
UA75520C2 (en) 2006-04-17
ZA200404999B (en) 2006-05-31
LU91534I2 (fr) 2009-04-27
JP2007186521A (ja) 2007-07-26
PT2045241E (pt) 2012-09-26
NO2009013I2 (no) 2012-08-27
US20030158246A1 (en) 2003-08-21
CA2471952C (en) 2008-04-01
CN101092388A (zh) 2007-12-26
NL300377I2 (nl) 2009-08-03
WO2003062200A3 (en) 2003-12-04
RS62404A (en) 2006-12-15
PL370427A1 (en) 2005-05-30
IL162825A0 (en) 2005-11-20
DE60324767D1 (de) 2009-01-02
ES2391747T3 (es) 2012-11-29
PT1470107E (pt) 2009-01-30
CY2009004I1 (el) 2009-11-04
JP4008885B2 (ja) 2007-11-14
DK1470107T3 (da) 2009-03-09
EP1470107A2 (en) 2004-10-27
TW200302090A (en) 2003-08-01
US20120115921A1 (en) 2012-05-10
GEP20074078B (en) 2007-03-26
FR09C0010I2 (enrdf_load_html_response) 2009-12-18
US20100081696A1 (en) 2010-04-01
CY1108841T1 (el) 2011-04-06
TWI259080B (en) 2006-08-01
SI2045241T1 (sl) 2012-11-30
CY2009004I2 (el) 2009-11-04
CN1902176A (zh) 2007-01-24
HRP20040665B1 (en) 2012-11-30
EG24978A (en) 2011-04-03
NO327322B1 (no) 2009-06-08
NO20043536L (no) 2004-08-24
SI1470107T1 (sl) 2009-04-30
ES2316717T3 (es) 2009-04-16
NO2009013I1 (no) 2009-06-29
PE20030982A1 (es) 2003-11-19
PL208527B1 (pl) 2011-05-31
IS8887A (is) 2010-03-01
CY1113330T1 (el) 2016-06-22
NO20071193L (no) 2004-08-24
KR100859230B1 (ko) 2008-09-18
HRP20040665A2 (en) 2005-04-30
KR20040075109A (ko) 2004-08-26
WO2003062200A2 (en) 2003-07-31
NL300377I1 (nl) 2009-05-06
AR038136A1 (es) 2004-12-29
IL188844A0 (en) 2009-02-11
AU2003202343B2 (en) 2007-07-12
US7317036B2 (en) 2008-01-08
US7618994B2 (en) 2009-11-17
US20050124680A1 (en) 2005-06-09
RS20100338A (en) 2011-06-30

Similar Documents

Publication Publication Date Title
BE2019C547I2 (enrdf_load_html_response)
BE2019C510I2 (enrdf_load_html_response)
BE2018C021I2 (enrdf_load_html_response)
BE2017C049I2 (enrdf_load_html_response)
BE2017C005I2 (enrdf_load_html_response)
BE2016C069I2 (enrdf_load_html_response)
BE2016C040I2 (enrdf_load_html_response)
BE2016C013I2 (enrdf_load_html_response)
BE2015C078I2 (enrdf_load_html_response)
BE2016C002I2 (enrdf_load_html_response)
BE2018C018I2 (enrdf_load_html_response)
BE2015C017I2 (enrdf_load_html_response)
BE2014C053I2 (enrdf_load_html_response)
BE2014C051I2 (enrdf_load_html_response)
BE2014C041I2 (enrdf_load_html_response)
BE2014C030I2 (enrdf_load_html_response)
BE2014C016I2 (enrdf_load_html_response)
BE2014C015I2 (enrdf_load_html_response)
BE2013C063I2 (enrdf_load_html_response)
BE2013C039I2 (enrdf_load_html_response)
BE2011C038I2 (enrdf_load_html_response)
FR09C0010I1 (enrdf_load_html_response)
BE2015C067I2 (enrdf_load_html_response)
BE2013C046I2 (enrdf_load_html_response)
JP2002273889A5 (enrdf_load_html_response)